Project Details
Description
A Phase III, Open Label Study to Evaluate the Safety and Efficacy of INSTILADRIN?? (rAd-IFN/Syn3) Administered Intravesically to Patients with High Grade, BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC).
| Status | Finished |
|---|---|
| Effective start/end date | 9/15/16 → 5/1/23 |
Funding
- FKD THERAPIES OY
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.